Carolina Medical Products, Inc. (CMP) has officially changed its name to CMP Pharma. This new name more appropriately reflects the nature of its current business as a specialty pharmaceutical company focused on niche products that address critical patient needs. The company manufactures and markets leading high-quality branded and generic, prescription and non-prescription drugs to the hospital, long-term care, and retail markets.
Commenting on the name change, Gerald Sakowski, CEO of CMP Pharma said, “We are confident that the new name provides a clearer picture of who we are today and where the business is headed in the future. We will continue to work with the marketplace – physicians, pharmacists and consumers – to develop the dosage forms that best meet their particular needs.” Mr. Sakowski was named CEO of the company in July of 2013. He was formerly Executive Vice President of Commercial Operations at Metrics, Inc. Greenville, NC
CMP Pharma was founded by Henry Smith as Carolina Medical Products (CMP) Company in 1975 while he was a professor of drug manufacturing at the University of North Carolina at Chapel Hill’s School of Pharmacy. In 1982, CMP Pharma’s SPS® Suspension was the first FDA approved suspension form of Sodium Polystyrene Sulfonate for the treatment of hyperkalemia. Prior to the new dosage form approval, Sodium Polystyrene Sulfonate was only available as a powder for
suspension. In subsequent years, CMP has developed a range of products, both liquid and semi-solid, that serves markets ranging from hyperkalemia to contact dermatitis to tuberculosis.
For more information, contact Gerald Sakowski, CMP Pharma at 252-753-7111.